The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients

Martijn R. Meijerink, Hester van Cruijsen, Klaas Hoekman, Matthijs Kater, Cors Schaik, Jan Hein T.M. van Waesberghe, Giuseppe Giaccone, Radu A. Manoliu

Research output: Contribution to journalArticleAcademicpeer-review

71 Citations (Scopus)


The purpose of this study was to determine the feasibility of dynamic contrast-enhanced perfusion CT (CTP) in evaluating the hemodynamic response of tumors in the chest and abdomen treated with a combination of AZD2171 and gefitinib. Thirteen patients were examined just before and every 4-6 weeks after starting therapy. Following intravenous injection of a contrast agent, dynamic image acquisition was obtained at the level of a selected tumor location. To calculate perfusion, the maximum-slope method was used. Pre-treatment average perfusion for extra-hepatic masses was 84 ml/min/100 g, for liver masses arterial perfusion was 25 ml/min/100 g, and a portal perfusion of 30 ml/min/100 g was found. After the administration of AZD2171 and gefitinib, in extra-hepatic masses an initial decrease in perfusion of 18% was followed by a plateau and in liver masses an initial decrease of 39% within the lesions and of 36% within a rim region surrounding the lesions was followed by a tendency to recovery of hepatic artery flow. In conclusion, CTP is feasible in showing changes of perfusion induced by anti-angiogenic therapy.

Original languageEnglish
Pages (from-to)1700-1713
Number of pages14
JournalEuropean Radiology
Issue number7
Publication statusPublished - 1 Jul 2007


  • Computed tomography
  • Neoplasms
  • Perfusion

Cite this